News – Spire Advisory Group

November 1st, 2024 – It was a a pleasure partnering with Blueprint Creative Group and U.S. Trade and Development Agency (USTDA) on a US Vietnam Healthcare workshop.
It was enlightening to engage with the Vietnam Ministry of Health, the US FDA and private sector on challenges and opportunities in the era of AI and digital health.

April 4th, 2024 – Spire Advisory Group was delighted to contribute to the USTDA – Thialand MOH healthcare workshop in Bangkok by mobilising key stakeholders to the table. The most significant outcome from the various workshops involving government, industry and regulatory bodies is that incentivizing hashtaghealthinnovation is key to improving health outcomes and reducing costs in developing countries.

Hayward, Calif. – September 26th, 2022 – We are delighted to announce that Mawi DNA Technologies (Mawi), a medical device company focusing on the development of innovative technologies for biological sample collection announced today that it has signed Memorandum of Understanding (MoU) agreements with the Moroccan Ministry of Investment, Convergence and Public Policies as well as with the Moroccan Ministry of Industry and Commerce to explore a Joint Venture with Mawi’s local partner Biotessia to establish a state of the art manufacturing facility in Morocco to serve the African market.

“We are excited for the opportunity to expand into Africa through this Joint Venture with Biotessia as we feel our technology offers unique solutions that directly address the challenges of collecting viable biological samples throughout the African continent. Mawi’s core technology enables universal collection among family members and long term stability of collected samples at a wide range of temperatures, increasing access to essentially any population segment regardless of geography or location. This in turn improves potential health outcomes due to increased diversity in sample availability.” commented Dr. Bassam El Fahmawi, CEO at Mawi.

Mawi has developed iSWAB-Microbiome-EL, a product that is being extensively deployed worldwide for population-scale surveillance testing for infectious diseases, notably Covid-19 and its variants due to its unique properties of viral inactivation, non-toxic formation, and enabling labs to skip the RNA extraction step, reducing costs and increasing testing throughput. Mawi also has a broad portfolio of iSWAB sample collection technologies for mammalian DNA, RNA, intact cells, and microbiome (fecal, soil, surface, and skin), in addition to the HemaSure-OMICS whole blood collection technology allowing RNA, CTC, cfDNA, and genomic DNA to be isolated from a single sample. Mawi’s blood collection technology is already being deployed in Kenya for HIV monitoring.

Mohcine Jazouli, minister of Investment added that: “The exchange with MawiDNA and Biotressia was very promising and conducive to accelerate the project of building a manufacturing unit in Morocco.”

Dr. Hanane Chaibanou, CEO of Biotessia added: “This project is aligned with Biotessia’s strategy and Morocco’s vision to attract foreign investments and insure local health needs”.

December 23rd, 2021 – SPIRE Advisory Group is delighted to announce that it has entered an agreement with Mawi DNA (www.mawidna.com) to position the company’s DNA and RNA collection kits with international partners in Africa and the Middle East.

November 8th, 2021 – Hatim Chraibi, Managing Director at SPIRE Advisory Group, has joined the African Diaspora Network, as Executive in Residence, to manage the organization’s digital health pilot initiative. For more information, please visit: https://africandiasporanetwork.org/telehealth-pilot/